Biopharmaceutical company Ferring Pharmaceuticals on Wednesday announced a collaboration agreement with Igenomix to advance care in reproductive medicine and maternal health.
The two-year research collaboration will focus on the discovery of novel targets and disease mechanisms in infertility and pregnancy-related conditions, including preeclampsia, with the goal of developing innovative diagnostic and therapeutic strategies in these areas of high unmet need.
Under the agreement the partners plan to establish a research hub in Boston, bringing together scientists from both companies to investigate molecular signatures, develop novel functional genomic systems and create translational tools to study for embryo implantation, endometrial microbiome interaction and decidualization biology.
The collaboration combines Ferring's therapeutic expertise with Igenomix's diagnostic capabilities.
Sobi's Biologics License Application for NASP in uncontrolled gout accepted by FDA
Hydrosome Labs announces promising fermentation breakthrough with ultrafine bubbles
Ionis receives FDA Breakthrough Therapy designation for ION582 in Angelman syndrome
AMO Pharma signs licence agreement with PHRI and Venca Research Inc to advance new study in ARVC
Saol Therapeutics receives US FDA Complete Response Letter for SL1009 (DCA) in PDCD
Amgen and Kyowa Kirin release rocatinlimab study results in atopic dermatitis
Hemogenyx Pharmaceuticals partners with Made Scientific to advance CAR-T therapy
Lilly's Jaypirca delivers breakthrough results in front-line CLL trial